AbCellera Biologics Inc.

ABCLNASDAQBeobachtung

US$12.16

-2.72 % today

COMPANY DATA

Sector: HealthcareIndustry: BiotechnologyCountry: CACEO: Carl HansenEmployees: 562Market cap: 3.7 BIPO: 11/12/2020Web: www.abcellera.com

AbCellera Biologics Inc. ist im Bereich Healthcare / Biotechnology tätig und hat seinen Hauptsitz in Vancouver, Kanada. Das Unternehmen spezialisiert sich auf eine fortschrittliche Plattform zur Antikörperentdeckung, die mittels KI-gestützter Systeme natürliche Immunsysteme analysiert, um die Entwicklung neuer…

Brief assessment by a strategy agent, last updated on 03/08/2026. Not investment advice.

PRICE HISTORY

26/08/25+178.1 %26/08/26

1D

-2.8 %

1W

+1.2 %

1M

+131.5 %

6M

+281 %

YTD

+255.4 %

1Y

+178.1 %

2Y

+351.9 %

5Y

-30.9 %

10Y

–

EARNINGS

Next earnings date

05/11/2026 (in 71 days)

Volatility around earnings

~57% stronger price swings than usual

SCORES

Valuation

Valued significantly cheaper than its own historical average.

Why this value? Details with Pro only.

Trend

Very strong uptrend.

Why this value? Details with Pro only.

Quality

Average balance sheet quality.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Strong expected growth at a fair price.

Why this value? Details with Pro only.

Insider

Insiders are buying significantly more shares than they sell.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

Significantly more upgrades than downgrades from analysts recently.

Why this value? Details with Pro only.

Sentiment

Not enough data yet for an assessment.

Short Pressure

Persistently high short volume ratio, partly with a Reg SHO threshold listing.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

4 credits free on registration
Access to virtual portfolios and watchlist
No credit card, no payment details needed
No subscription, no minimum term
Our own servers in Germany, no US cloud

Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT ABCL

ANALYST ASSESSMENT

PRICE TARGET LOW

US$7.00

CONSENSUS

US$15.33

MEDIAN

US$9.00

PRICE TARGET HIGH

US$30.00

0

STRONG BUY

11

BUY

1

HOLD

0

SELL

0

STRONG SELL

12

TOTAL · Buy

DATE	ANALYST FIRM	RATING	ACTION
11/08/2026	Truist Securities	Buy	maintain
06/08/2026	Stifel	Buy	maintain
06/08/2026	Cantor Fitzgerald	Overweight	maintain
07/07/2026	Benchmark	Hold → Buy	upgrade
07/11/2025	Leerink Partners	Outperform → Market Perform	downgrade
08/08/2025	Stifel	Buy	maintain
14/07/2025	Keybanc	Overweight	maintain
16/05/2025	Truist Securities	Buy	maintain

METRICS

P/E

-22.52

P/B

4.15

EV/EBITDA

-23.26

RETURN ON EQUITY

-6.2 %

NET MARGIN

-1,368.6 %

DEBT/EQUITY

0.15

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

67.2 %

FLOAT SHARES

205,087,060

AVG. DAILY VOLUME (30D)

8,527,390

INSIDER TRANSACTIONS (SEC)

DATE	INSIDER	ROLE	TRANSACTION	SHARES	PRICE	PLAN TYPE
24/08/2026	Hayden Michael R	Director	Purchase	53,613	10.64	Spontaneous
18/08/2026	Montalbano John S.	Director	Purchase	10,000	11.03	Spontaneous
14/08/2026	Hayden Michael R	Director	Purchase	46,387	10.37	Spontaneous
14/08/2026	Booth Andrew	Officer	Purchase	37,200	10.32	Spontaneous
13/08/2026	Hayden Michael R	Director	Gift	50,000	0	Spontaneous

Page 1 / 2

ATTENTION

1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.8%

Search (Google Trends)

19/0727/0704/08

Forums (Reddit)

24/0825/08

INSTITUTIONAL HOLDERS

FUND / INSTITUTION	SHARES	CHANGE	AS OF
Advisory Services Network, LLC	0	-2,962	30/06/2026
QUADRANT CAPITAL GROUP LLC	0	-1,220	30/06/2026
Clearstead Advisors, LLC	0	-26	30/06/2026
Schonfeld Strategic Advisors LLC	0	-141,295	30/06/2026
Point72 Asset Management, L.P.	0	-1,149,325	30/06/2026

Page 1 / 3

Not investment advice. Past performance is not an indicator of future results.